Biolinerx announced the dosage of agi-134 to the first patient in the clinical study

Biolinerx Ltd., a clinical stage biopharmaceutical company focused on oncology, today announced the first patient to be treated in part 2 of the phase 1 / 2A clinical study of agi-134, a new drug Agi-134 is a compound that can induce direct antitumor response and vaccine effect through a unique multi arm mechanism targeting at new tumor antigens In the dose escalation part of the study completed earlier this month, agi-134 was found to be safe and well tolerated, with no serious adverse drug-related events or dose limiting toxicity reported Philip Serlin, CEO of biolinerx, said: "after successfully completing Part 1 of the study and determining the recommended dose, we are pleased to announce the start of Part 2 of phase 1 / 2a of our second oncology product agi-134 In preclinical trials, agi-134 caused primary tumor regression, prevented secondary tumor growth, and triggered vaccine action that might prevent future metastasis We look forward to the preliminary results of the second part of the study, which will be available around the end of 2020 " The ongoing phase 1 / 2A study, a multicenter, open label study, is expected to be conducted in approximately 15 locations in the United States, the United Kingdom and Israel The purpose of this study was to evaluate the safety and tolerability of agi-134 in a variety of solid tumor types, evaluate a variety of biomarkers, and verify the mechanism of action of agi-134 In addition, efficacy will be evaluated by clinical and pharmacodynamic parameters (Biovalley / BIOON Com) original source: biolinerx official website